P
MDGL icon

&Partners’s Madrigal Pharmaceuticals MDGL Stock Holding History

&Partners’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$239K Sell
447
-73
-14% -$37.4K ﹤0.01% 2277
2026
Q1 		$272K Buy
520
+11
+2% +$5.25K ﹤0.01% 2058
2025
Q4 		$296K Buy
+509
New +$260K ﹤0.01% 1919

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

&Partners's MDGL Position: Q2 2026 in Review

&Partners reduced its Madrigal Pharmaceuticals (MDGL) stake by 14% in Q2 2026, selling an estimated $37.4K and leaving 447 shares worth $239K. The position accounts for ﹤0.01% of the portfolio, ranked #2277.

&Partners first reported a position in MDGL in Q4 2025 and has held it in 3 quarters since. The position peaked at $296K in Q4 2025. 415 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

  • &Partners held 447 shares of Madrigal Pharmaceuticals worth $239K as of Q2 2026.
  • &Partners sold 73 Madrigal Pharmaceuticals shares in Q2 2026, an estimated $37.4K.
  • Madrigal Pharmaceuticals made up ﹤0.01% of &Partners's portfolio in Q2 2026, its #2277 holding.
  • &Partners first reported a position in Madrigal Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • &Partners's Madrigal Pharmaceuticals position peaked at $296K in Q4 2025.
  • 415 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on &Partners's 13F filing for Q2 2026, filed 14 Aug 2026.